Enjoy complimentary customisation on priority with our Enterprise License!
The global immunoglobulin products market size is estimated to grow by USD 9.70 billion, at a CAGR of 10.11% between 2023 and 2028. It also includes an in-depth analysis of drivers, trends, and challenges. Our market forecasting report examines historical data from 2018-2022, besides analyzing the current market scenario.
The increasing number of new product launches by market players as pharmaceutical companies introduce new formulations, delivery methods, and indications for immunoglobulin therapies, expand treatment options, and address unmet medical needs across diverse patient populations. For instance, in January 2024, CSL Ltd. launched a subcutaneous immunoglobulin, i.e., a prefilled syringe of Hizentra, for the treatment of CIPD and primary immunodeficiency. Furthermore, the introduction of novel immunoglobulin products enhances market dynamics by promoting advancements in efficacy, safety profiles, and patient convenience. These factors will drive the growth of the market during the forecast period.
To learn more about this market forecast report, Download Report Sample
The market is a vital component in the treatment landscape, catering to various conditions like Guillain-Barre syndrome, Primary immunodeficiency disease, and Immune thrombocytopenic purpura. With the advent of Treatment with Anti-Coronavirus Immunoglobulin, the market has witnessed a surge in demand. Chronic inflammatory demyelinating polyneuropathy and Multifocal motor neuropathy also benefit from treatments like Intravenous immunoglobulin (IVIG), showcasing its immunomodulatory properties.
The market share growth by the IgG segment will be significant during the forecast period. IgG is the most abundant antibody isotype in the human body, which plays a crucial role in immune response and defense against pathogens. IgG products are derived from pooled plasma donations and are available in various formulations, including IV, SC, and IM preparations.
Get a glance at the market contribution of various segments Download the PDF Sample
The IgG segment was valued at USD 8.98 billion in 2018. Further, the IgG product segment continues to witness steady growth driven by factors, such as the increasing prevalence of immune-related disorders, growing awareness about immunoglobulin therapies, and advancements in biotechnology, which are leading to the development of novel formulations and delivery methods. These factors will drive the growth of the IgG segment of the market during the forecast period.
Intravenous (IV) administration of immunoglobulin products is crucial for the swift distribution of therapeutic antibodies, vital for autoimmune diseases, primary immunodeficiencies, and neurological disorders. Major players like CSL Ltd., Grifols SA, and Takeda Pharmaceutical Co. Ltd. offer high-quality IVIG therapies, prioritizing safety and efficacy. Advancements in formulations enhance stability and reduce infusion times, improving patient convenience. With rising immune-related disorders globally, IV administration remains pivotal, with innovative therapies propelling market growth during the forecast period.
Subcutaneous (SC) administration of immunoglobulin products provides a convenient and effective alternative to IV infusion, delivering therapeutic antibodies into the bloodstream gradually. Beneficial for primary immunodeficiencies and autoimmune conditions, SCIG therapy offers flexible dosing schedules and reduced treatment burden. Also, SCIG therapies enable home-based administration, improving patient independence and quality of life. Ongoing research drives the refinement of SCIG formulations to meet evolving patient needs, fueling the market growth during the forecast period.
For more insights about the market share of various regions Download PDF Sample now!
North America is estimated to contribute 35% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. North America's immunoglobulin products market burgeons due to heightened adoption. Key drivers include escalating disease prevalence - cancer, autoimmune, metabolic, musculoskeletal, CNS, and blood disorders. Healthcare reforms spur demand, benefiting insured and uninsured populations. Population growth, economic stability, and robust healthcare infrastructure offer growth prospects. Rising R&D spending, favorable government funding, and key player presence propel market expansion. The region's high prevalence of autoimmune, immunodeficiency, and neurological conditions boosts immunoglobulin therapy demand. Biotechnological advancements, healthcare innovation, and robust R&D further fuel market growth.
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:
Other companies include:
Bio Products Laboratory Ltd., Biocon Ltd., CSL Ltd., GC Biopharma Corp. , Grifols SA, Kedrion S.p.A, LFB SA, Novartis AG, Octapharma AG, Pfizer Inc., Serum Institute of India Pvt. Ltd., Shanghai RAAS Blood Products Co. Ltd., Taibang Biological Group Co. Ltd., Taj Pharmaceuticals Ltd., and Takeda Pharmaceutical Co. Ltd.
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
In the market, Hospitals, clinics, and homecare settings rely on Plasma collection to meet demand, with products like Octogam 10% IVIg playing a crucial role. Regulatory bodies like the Disease Control and Prevention (CDC) and Medicare & Medicaid Services (CMS) oversee quality standards, ensuring patient safety and efficacy in this dynamic market. Our researchers analyzed the market research and growth data with 2023 as the base year, along with the key market growth analysis, trends, and challenges. A holistic analysis of drivers, trends, and challenges will help companies refine their marketing strategies to gain a competitive advantage.
The growing geriatric population is the key factor driving the market. The expanding elderly population is a key driver of global immunoglobulin product market growth due to increased susceptibility to immunodeficiency disorders, autoimmune diseases, and age-related conditions necessitating immunoglobulin therapy. Globally, the proportion of individuals aged 65 and above is rising steadily, attributed to declining fertility rates and healthcare advancements leading to extended life expectancy. Aging entails natural immune function decline (immunosenescence), heightening infection, and immune disorder risks.
Thus, such a demographic exhibits a higher prevalence of immunodeficiency disorders like hypogammaglobulinemia and autoimmune diseases such as rheumatoid arthritis, lupus, and inflammatory bowel disease. Consequently, the demand for immunoglobulin therapies to manage these conditions and preserve the quality of life rises. Additionally, neurological conditions like CIDP and GBS, prevalent in older adults, further drive immunoglobulin therapy necessity. With global aging trends persisting, immunoglobulin product demand for age-related conditions is poised to escalate, fueling market growth.
Advancements in biotechnology and manufacturing processes is the primary trend shaping the market. Advancements in biotechnology and manufacturing processes propel growth in the global immunoglobulin products market by enhancing therapy safety, efficacy, and quality. Innovations like recombinant DNA technology and protein engineering enable the creation of next-gen immunoglobulin products with improved properties.
Further, leading biopharmaceutical companies such as CSL Ltd., Takeda Pharmaceutical Co. Ltd., Grifols SA, and Octapharma AG leverage these advancements to develop cutting-edge therapies like Privigen, Gamunex-C, Flebogamma DIF, and Octagam. These products undergo stringent quality control to ensure safety and efficacy. By utilizing state-of-the-art plasma fractionation and purification techniques, these companies deliver consistent treatment options for various medical conditions, improving patient outcomes globally. Commitment to innovation in biotechnology and manufacturing drives market growth during the forecast period.
Competition from biosimilar products and other alternative therapies is the major challenge that affects the market. Biosimilar immunoglobulin products, akin to existing reference therapies, offer a cost-effective alternative to branded counterparts. Rigorous comparative assessments ensure their similarity in quality, safety, and efficacy, enabling entry into the market at reduced prices. This fosters competition, driving down costs and enhancing cost-effectiveness for healthcare providers and patients.
However, the availability of alternative therapies, including oral medications, immunosuppressants, and gene therapies, presents challenges. Patients may opt for these alternatives based on medical conditions and treatment preferences, diversifying treatment options. This, coupled with biosimilar emergence, poses strategic challenges for immunoglobulin manufacturers. Consequently, competition from biosimilars and alternative therapies impedes market growth, influencing pharmaceutical strategies during the forecast period.
The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the market growth and forecasting report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Customer Landscape
The market research report provides comprehensive data (region wise segment analysis), with forecasts and estimates in "USD Billion" for the period 2024-2028, as well as historical data from 2018 - 2022 for the following segments.
The market addresses various conditions like Guillain-Barré Syndrome, Multifocal motor neuropathy (MMN), Common Variable Immunodeficiency (CVID), and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). With Anti-inflammatory properties and treatments for HIV and Respiratory syncytial virus (RSV), it plays a pivotal role in healthcare. Regulatory processes like Biologics License Application (BLA) ensure safety standards. Conditions such as Myasthenia Gravis (MG) and Immune Thrombocytopenic Purpura (ITP) find relief through immunoglobulin therapies, reflecting its significance in managing immunodeficiency diseases like Agammaglobulinemia.
Further, the global immunoglobulin market caters to a wide range of conditions, including Guillain-Barre syndrome, Primary immunodeficiency disease, and Immune thrombocytopenic purpura (ITP). It provides essential therapies like Plasma treatments, including Treatment with Anti-Coronavirus Immunoglobulin for severe cases. Moreover, Chronic inflammatory demyelinating polyneuropathy (CIDP) and Multifocal motor neuropathy (MMN) are among the disorders benefiting from immunoglobulin therapies. These treatments are administered in various settings such as Hospitals, Clinics, and Homecare, ensuring accessibility for patients with immunodeficiency diseases like immunodeficiency disease (SID).
Market Scope |
|
Report Coverage |
Details |
Page number |
169 |
Base year |
2023 |
Historic period |
2018-2022 |
Forecast period |
2024-2028 |
Growth momentum & CAGR |
Accelerate at a CAGR of 10.11% |
Market Growth 2024-2028 |
USD 9.70 billion |
Market structure |
Concentrated |
YoY growth 2023-2024(%) |
8.65 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 35% |
Key countries |
US, Germany, UK, China, and Japan |
Competitive landscape |
Leading companies, Market Positioning of companies, Competitive Strategies, and Industry Risks |
Key companies profiled |
ADMA Biologics Inc., Bio Products Laboratory Ltd., Biocon Ltd., CSL Ltd., GC Biopharma corp. , Grifols SA, Kedrion S.p.A, LFB SA, Novartis AG, Octapharma AG, Pfizer Inc., Serum Institute of India Pvt. Ltd., Shanghai RAAS Blood Products Co. Ltd., Taibang Biological Group Co. Ltd., Taj Pharmaceuticals Ltd., and Takeda Pharmaceutical Co. Ltd. |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period. |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Download the Sample PDF at your Fingertips
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Product
7 Market Segmentation by Route of Administration
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.